Rallybio Corporation (RLYB)

1.6250 +0.0350 (+2.20%) As of 01:25PM EDT. Market open.

Rallybio Corporation

234 Church Street
Suite 1020
New Haven, CT 06510
United States
203 859 3820
https://www.rallybio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 30

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Martin W. MacKay Ph.D.	Co-Founder & Executive Chairman	723.35k	N/A	1956
Dr. Stephen Uden M.B, M.D.	Co-Founder, President, CEO & Director	723.35k	N/A	1958
Mr. Jonathan I. Lieber M.B.A.	CFO & Treasurer	667.13k	N/A	1970
Dr. Steven W. Ryder F.A.C.P, M.D.	Chief Medical Officer	680.22k	N/A	1952

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Corporate governance

Rallybio Corporation’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.